Name: Latest research reports of Laurus Labs Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Laurus Labs Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Laurus Labs Ltd.

NSE: LAURUSLABS | BSE: 540222 | ISIN: INE947Q01028 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

821.8500 -16.40 (-1.96%)

NSE Aug 08, 2025 15:31 PM

96.76% Gain from 52W Low

Volume: 1.1M

Laurus Labs Ltd.

28 Jul 2022

821.85

-1.96%

Laurus Labs (BUY): Synthesis business saves the day

Buy: Laurus Labs Ltd.

Recommendation

BOB Capital Markets Ltd.

Q1 revenue/EBITDA came in 5%/8% above consensus and grew 20%/ 15% YoY to Rs 15.4bn/Rs 4.5bn

Laurus Labs Ltd. has an average target of 686.25 from 4 brokers.